NEWS

In a thought-provoking perspective for the British Journal of Cancer, Dr. Karim Budhwani jumps into the future with a slingshot stretching back 2,000 years, from Aristotle to AI in medicine. Blending the scientific method with emerging synthetic intelligence, ‘The Scienthetic Method’ explores how we can synergize AI with human wisdom to transcend limitations of the hypothesis-driven approach in an exponentially expanding data universe, while mitigating the risks of artificial ignorance.

With the theme “Rebuilding: What’s Next for Biotech,” the Summit focuses on the future of biotech, covering topics such as the biotech IPO outlook, developments in cell therapy and the transition from corporate communications to corporate affairs. Dr. Karim Budhwani, CEO-Scientist of CerFlux, will chair the Early Stage Development track and lead the panel discussion titled, "Decoding AI in Drug Development: Going Beyond the Hype" with experts from Alkermes, Regeneron Genetics Center, Formation BIO, and Insilico Medicine.

Precision medicine and artificial intelligence (AI) are ushering in major changes in oncology. Precision medicine is an innovative medicinal approach that moves away from a one-size-fits-all strategy to personalized treatments that account for the patient’s genetics. “We have a clear choice,” Budhwani said. “We can either harness these transformative technologies to shape the future of medicine or we can watch from the sidelines as others seize the opportunity to make a global and generational impact. This panel discussion is about this choice—about positioning biotech leaders to take maximum advantage of these technologies to crush cancer.”

"CerFlux exemplifies the type of innovative company, with the potential to make a profound impact globally, that the Innovate Alabama Supplemental Grant Program aims to support," said Innovate Alabama CEO Cynthia Crutchfield. "We're excited to partner with CerFlux as they continue to develop transformative technologies and create new jobs and opportunities in Alabama."

Scenes from the BIO International Convention 2023 panel, "Is Your Billion-Dollar Oncology AI Cutting-Edge Technology or is it Artificial Ignorance?" moderated by Dr. Karim Budhwani (CEO-Scientist at CerFlux) with expert panelists Dr. Maggie Scully (Director of Partnership Development at Frederick National Lab for Cancer Research), Tahera Kan, MBA, MS (VP of Precision Medicine and Enabling Technology at Johnson & Johnson), and Dr. Sandeep Menon (Chief Scientific Officer of AI and Digital Science at Pfizer).

To understand the importance of funding research, we spoke with Dr. Karim Budhwani, CEO-Scientist at CerFlux in Birmingham. “Recent advances in technology are opening doors to precision personalized oncology which was not possible before. This is why investing in cancer research is critical, now more than ever, to take advantage of new technologies so no one has to endure ineffective treatment or wipe out their life savings while fighting the ’emperor of all maladies’.” BCRFA has been partnered with Budhwani since CerFlux’s start.

We are in the midst of a historic moment in the life sciences sector. Newsweek will be hosting a panel discussion at the upcoming BIO International Convention in San Diego. This is one of the largest, most-comprehensive events for the biotech industry, attended by over 20,000 industry leaders from across the globe. Newsweek Senior Science Reporter Pandora Dewan will be joined by five industry experts to discuss the promises and challenges of these future innovations and, most importantly, how they can be delivered to those who need them. Although the event is sold out, a recording will be available on Newsweek's YouTube channel after the event.

This is Dr. Budhwani's third consecutive year leading a panel at BIO International Convention. The panel will include leaders from Johnson & Johnson, Frederick National Laboratory (FNL) for Cancer Research, and Alnylam. The panel titled, "The Oncology Endgame: Assemble and Shine with Precision Medicine, or Lose." will focus on how AI can improve cancer drug research and address challenges facing biotech and pharmaceutical companies. “We must ensure we are utilizing all available tools in our fight against cancer, including advancements in AI,” said Dr. Scully, Partnership Director at FNL.

The Breast Cancer Research Foundation of Alabama (BCRFA) proudly announces its commitment to advancing breast cancer research in Alabama through a substantial investment of $1,250,000 in 2023. This grant will support 35 cutting-edge research projects at 8 esteemed institutions, further powering a future free from breast cancer. Among the beneficiaries are Alabama State University, CerFlux, HudsonAlpha Institute, Tuskegee University, O’Neal Comprehensive Cancer Center, University of Alabama, and Mitchell Cancer Institute.

“Applying AI has tremendous potential in our fight against cancer, from improving screening to predicting treatment outcomes,” said Dr. Scully, FNL’s partnership development manager. “To bolster that potential, the field has seen innovative partnership models and training activities targeting previously untapped talent pools.” Dr. Budhwani, CEO of CerFlux added, “These dialogues are extremely important in how we shape this landscape, because there is no mistaking that we will shape the landscape.”

The BBJ's Inno Under 25 spotlight showcases some of the most promising young innovators. Dana Zuaiter, speaking from her perspective at CerFlux, said, "I believe that innovation is vital to society because it gives each person a window to create or discover something that will benefit the greater good. That’s important in Birmingham because this city is equipped with many intelligent minds; when innovation is valued and promoted, more people will have the resources and support to share their ideas allowing for a window of advancement to be open to all."

CerFlux will be joining biotech industry leaders and investors in a series of events hosted alongside BIO International Convention. These events will be aimed at accelerating advances in biotech and life sciences across several themes including AI/ML and precision personalized medicine in oncology.

When you think of Alabama technology, you may conjure sepia-toned images of Carver’s zany peanut inventions or grainy footage of the first moon landing. What you may not realize, is how Alabamians today continue to generate world-changing technologies. The Innovate Alabama Supplemental Grant recipient, CerFlux, is changing the way cancer can be treated by developing a personalized test for more precise treatment for each patient’s unique cancer.

CerFlux ChipMux technology addresses the critical, urgent, and unmet need for accessible and affordable predictive technologies that identify optimal therapy regimens and strategically eliminate ineffective options. This represents a major departure from the generalized one-size-fits-none approach to cancer treatment. This endeavor is further enhanced by a commercial-academic collaboration with the James Comprehensive Cancer Center at the Ohio State University.

“Billions of dollars and FOMO investor zeal frantically chasing the promise of artificial intelligence have been snared instead in 'artificial ignorance',” Budhwani said. "But pausing AI in oncology is not an option. In fact, we have to find ways to accelerate the responsible use of AI to maximize benefits and improve patient outcomes.” The panel will explore how AI can revolutionize cancer drug discovery, the market potential for biotech and pharmaceutical companies, and the challenges that must be overcome to realize these benefits.